2025 EGASP Data Report Launch Webinar
Table of Contents
The World Health Organization (WHO) department for HIV, Tuberculosis, Hepatitis and Sexually Transmitted Infections, in collaboration with the Antimicrobial Resistance Department, is hosting a webinar to launch the 2025 Data Report on the Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP).
Understanding the Enhanced Gonococcal Antimicrobial surveillance Programme (EGASP)
EGASP is a crucial initiative focused on strengthening national capabilities in STI surveillance, epidemiology, and monitoring antimicrobial resistance (AMR) in gonorrhoea. It aims to develop technical expertise across clinical, epidemiological, and laboratory settings.
key Objectives of EGASP
- Strengthen national STI surveillance systems.
- Monitor the epidemiology of gonorrhoea.
- Track antimicrobial resistance patterns in Neisseria gonorrhoeae.
- Build technical skills among healthcare professionals.
EGASP data are increasingly vital for informing updates to national STI treatment guidelines and supporting reviews of both national and global recommendations for gonorrhoea testing and treatment.
Webinar Timing & World Antimicrobial Awareness Week
This launch event is strategically scheduled during World Antimicrobial Awareness Week (WAAW) 2025. The theme for WAAW 2025 is “Accelerate action to Combat Antimicrobial Resistance.” This highlights the urgent need to address the growing threat of AMR, including in sexually transmitted infections like gonorrhoea.
The Importance of Gonorrhoea Surveillance
Gonorrhoea is a notable public health concern globally. Increasing antimicrobial resistance poses a serious challenge to effective treatment. Without robust surveillance systems, it becomes difficult to track the spread of resistant strains and implement appropriate control measures.
Why is AMR in Gonorrhoea a Concern?
Antimicrobial resistance in gonorrhoea means that the antibiotics traditionally used to treat the infection are becoming less effective. This can lead to:
- Treatment failures.
- Increased complications.
- Higher rates of transmission.
- Greater healthcare costs.
How EGASP Data is Used
The data collected through EGASP plays a critical role in several areas:
Informing national STI treatment guidelines based on local resistance patterns.
Supporting the development of global recommendations for gonorrhoea testing and treatment.
Identifying emerging resistance trends and outbreaks.
Evaluating the effectiveness of interventions to control gonorrhoea and AMR.
Key Takeaways
- EGASP is a vital WHO program for monitoring gonorrhoea and antimicrobial resistance.
- The 2025 Data Report will provide valuable insights into the current state of gonorrhoea globally.
- World Antimicrobial Awareness week underscores the urgency of addressing AMR.
- Effective surveillance is essential for guiding treatment policies and controlling the spread of resistant strains.
Frequently Asked Questions (FAQ)
- What is the primary goal of EGASP?
- To strengthen national capacity for STI surveillance and monitor antimicrobial resistance in gonorrhoea.
- Why is World Antimicrobial Awareness Week vital?
- It raises awareness about the global threat of antimicrobial resistance and promotes responsible antibiotic use.
- Who should attend the webinar?
- Healthcare professionals involved in STI diagnosis, treatment, surveillance, and laboratory testing.